Mitchell Young Williams Sells 263,863 Shares of Biosig Technologies (NASDAQ:STEX) Stock

Biosig Technologies, Inc. (NASDAQ:STEX) CIO Mitchell Young Williams sold 263,863 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $0.79, for a total value of $208,451.77. Following the completion of the transaction, the executive directly owned 3,037,648 shares of the company’s stock, valued at $2,399,741.92. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Biosig Technologies Stock Performance

Shares of NASDAQ STEX opened at $0.92 on Wednesday. Biosig Technologies, Inc. has a fifty-two week low of $0.70 and a fifty-two week high of $14.11. The stock has a market capitalization of $166.29 million, a PE ratio of -0.10 and a beta of 1.58. The company has a fifty day moving average of $1.47.

Biosig Technologies (NASDAQ:STEX) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($8.23) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on STEX shares. Needham & Company LLC cut their price objective on shares of Biosig Technologies from $12.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Wall Street Zen lowered shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a report on Sunday, April 5th. Finally, Weiss Ratings raised shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.00.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.